Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-23 first-line axi-cel versus standard of care in high-risk large B-cell lymphoma
NL-OMON60249Phase 3Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Oct 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma comparing Axicabtagene ciloleucel with Standard of care therapy (2 arms). Primary endpoint: Event-free survival. Started Oct 2023; status: active, not recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on NL-OMON60249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60249.